Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm epratuzumab in Waldenström's macroglobulinemia
2004-001563-21Phase 2Active
- Sponsor
- Gilead Sciences
- Start
- May 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epratuzumab in Waldenström macroglobulinemia (WM), sponsored by Gilead Sciences. Primary endpoints: Overall response rate, Duration of response and 5 more. Started May 2005; status: active.
02
Drugs
epratuzumab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2004-001563-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001563-21.